AJP - Regu Fuel your research with LabChart
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


Am J Physiol Regul Integr Comp Physiol 236: R137-R141, 1979;
0363-6119/79 $5.00
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by DiStefano, J. J.
Right arrow Articles by Mak, P. H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by DiStefano, J. J., 3rd
Right arrow Articles by Mak, P. H.

AJP - Regulatory, Integrative and Comparative Physiology, Vol 236, Issue 3 137-R141, Copyright © 1979 by American Physiological Society


ARTICLES

On model and data requirements for determining the bioavailability of oral therapeutic agents: application to gut absorption of thyroid hormones

J. J. DiStefano 3rd and P. H. Mak

A two-pool model is proposed as a first approximation of the dynamics of thyroid hormone dissolution and absorption in the human gut. It is shown that this model, or any more complex one of the same process, must be imbedded in a larger whole-body model for the purpose of quantifying its parameters. Parameter identification experiments are designed with the aid of identifiability analysis and a complete quantification is obtained, for both triiodothyronine (T3) and thyroxine (T4) absorption, using kinetic data obtained from the literature. The average percent absorption of oral dosages calculated from the model for T3 (95.8%) and for T4 (49.3%) are exceptionally close to reported measured values. Other data not used in model development also serve to validate the results, for use in applications not demanding greater physiological detail, such as for determining the bioavailability of orally administered hormones, or for the "inverse problem," computing optimal dosage regimens for hormone therapy.





HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Visit Other APS Journals Online